CompletedNot Applicable

AssocIation of PULSatility and Occurrence of Complications Related to Mechanically Assisted Circulatory Support

France27 participantsStarted 2021-12-02

Plain-language summary

The primary objective of this study is to determine whether preserved pulsatility for patients supported by CF-LVAD (continuous flow Left Ventricular Assist Device) is associated with less acquired deficiency of the Von Willebrand factor, a blood glycoprotein involved in hemostasis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients over 18 years of age
✓. Patients for whom a decision to implant a left-sided monoventricular assist has been retained after discussion in the RCP of heart failure, transplantation and circulatory assistance (whatever the therapeutic strategy envisaged: waiting for transplantation, recovery or destination therapy).
✓. Patients affiliated to a social security system (beneficiaries or beneficiaries entitled to benefits, excluding AME)
✓. Signature of an informed consent by the patient or by the trusted person, or a close relative, if the patient is not able to do so

Exclusion criteria

✕. Heart transplant patients
✕. Patients who already had LVAD
✕. Chronic renal failure patients on dialysis
✕. Patients refusing to give informed consent
✕. Patients deprived of liberty or under legal protection (guardianship, curators)
✕. Pregnant or breastfeeding women
✕. Ongoing participation in another intervention research protocol except LEVOECMO project (NCT04728932) and ANCHOR project (NCT04184635)

What they're measuring

Von Willebrand factor high molecular weight multimers (HMWM) ratio

Timeframe: 30 days after LVAD IMPLANTATION

Trial details

NCT IDNCT04951999

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-07-24

View on ClinicalTrials.gov More End-stage Heart Failure trials